article = {SCR-2021-8-121}
title = {Cecal Perforation in a COVID-19 Patient Treated with Tocilizumab: A Case Report}
journal = {Surgical Case Reports}
year = {2021}
issn = {2613-5965}
doi = {http://dx.doi.org/10.31487/j.SCR.2021.08.21}
url = {https://www.sciencerepository.org/cecal-perforation-in-a-covid-19-patient-treated-with-tocilizumab_SCR-2021-8-121 
author = {Victor Dominguez Prieto,Cecilia Meliga,Sara Rosenstone,Siyuan Qian Zhang,Manuel Escanciano Escanciano,Felipe Velez Pinto,Sergio Hernandez Villafranca,Sara Gonzalez Soares,Javier Barambio Buendia,Miguel Leon Arellano,Damian Garcia Olmo,Ricardo Pardo Garcia,Hector Guadalajara Labajo,}
keywords = {COVID-19, tocilizumab, interleukin-6, gastrointestinal perforation}
abstract ={Tocilizumab is a monoclonal antibody against the interleukin-6 receptor. Gastrointestinal perforation has been associated with Tocilizumab treatment. In the absence of specific antiviral drugs, Tocilizumab is currently being used as a treatment option in patients with severe COVID-19 pneumonia. This is being based on the implication of interleukin-6 in the aberrant host immune response that characterizes the disease and initiates patients' lung damage. Herein we present the case of a cecal perforation in a patient treated with Tocilizumab for COVID-19. In such context, we expect that there may be an increase in the incidence of gastrointestinal perforation related to Tocilizumab.}